Acrivon Therapeutics heads into its May 15 Q1 earnings call carrying two competing stories: a major institutional backer just bought $7 million worth of stock at the open, while short sellers are quietly adding to a position that has climbed to an 11-year high relative to the float.
The dominant ownership story is RA Capital. The healthcare-focused fund spent $7.0 million on April 22, picking up 3.89 million shares at $1.80 each. That purchase lifted RA Capital's total holding to 28.6% of the company — the largest institutional block by a wide margin. The timing matters: the buy came two days before short interest broke above 11% of the free float, suggesting RA Capital saw value ahead of what the rest of the market was beginning to bet against. Net insider buying over the past 90 days was just over $7 million, almost entirely attributable to that single transaction.
Short positioning has been building steadily. SI % FF hit 11.4% on May 12, up from around 9.6% on April 22 — the same day RA Capital filed its purchase. The short base was already elevated at roughly 10.4% in early April; the step-up through late April and into May represents a fresh increment rather than a sudden squeeze of new entrants. Short interest is up about 10% over the past month in share terms. That said, the borrow market remains orderly. Cost to borrow is running just above 4%, well below the 5%-plus levels seen in early April, and availability is comfortable enough that short sellers are not facing meaningful squeeze pressure. The ORTEX short score ticked up to 66 on May 12, its highest reading of the past ten days.
On the Street, the analyst data available through early April points broadly positive — coverage carries Buy or Outperform ratings from Piper Sandler, HC Wainwright, Oppenheimer, and Cantor Fitzgerald. However, the most recent analyst data is over six weeks old, so these should be treated as background context rather than fresh conviction. Most targets were set well above the current $1.89 share price — the Piper Sandler target was raised to $8 in January — though the stock has remained under $2 for much of 2026. Factor scores are mixed: EPS momentum over 90 days ranks in the 71st percentile, and EPS surprise is at the 68th percentile. Forward EPS growth scores are weak at the 18th percentile.
The earnings reaction history offers a wide range. The last four events produced moves of -9.2%, +1.2%, +15.0%, and -1.8% on day one. The five-day picture is similarly scattered: +10.6%, -13.4%, +11.1%, -0.9%. A single-digit day-one move in either direction fits the historical pattern, but a double-digit reaction is not without precedent here. Tuesday night's Q1 print already landed — EPS of -$0.49 beat the -$0.53 estimate, and the company highlighted progress on "key 2026 clinical catalysts" alongside the results. The stock had drifted 9% lower on the week heading into that release, so the beat provides at least a technical floor going into the formal May 15 call.
Close peers were mostly lower on the week. ZYME shed more than 10%, JSPR fell 5.6%, and ABEO dropped 2.6%. GNLX was the outlier, gaining 7.2%. ACRV's 9% weekly decline put it roughly in line with the weakest names in the group, though the EPS beat may shift that picture as the May 15 call unfolds.
The May 15 investor call is now the immediate focus — the market will be watching whether management can translate a narrower-than-expected loss into a cleaner catalyst timeline for 2026.
See the live data behind this article on ORTEX.
Open ACRV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
